In the past 25 years, Prof. Dr. M Claeys has built up research expertise in the field of acute coronary syndromes and valvular heart diseases. Within the domain of acute coronary syndromes, he has rolled out the following clinical / translational lines of research - ischemia-reperfusion injury: both pathophysiological and therapeutic aspects were investigated through both local and international projects. He is currently studying the potential utility of ischemic conditioning in patients with an acute heart attack (CARIOCA study). - Influence of environmental factors (air pollution, climate, temperature) on the development of an acute heart attack. He is currently involved in a large-scale national project (EMIR study) on this social theme. - Anticoagulation policy in patients with acute coronary syndromes treated with a coronary stent. He is involved as a principal investigator or national coordinator in studies with platelet inhibitors and / or oral anticoagulants. An international study of NOAC is currently being conducted in patients with atrial fibrillation and acute coronary syndromes (ENTRUST-AF). - STEMI network and quality indicators: he is the founder and driving force behind the Belgian STEMI database where quality is evaluated through the collection of quality indicators within a certain network. This STEMI database with currently hosts more than 30,000 patients is also a source for scientific studies on subareas of the acute heart attack (e.g. shock, cardiac arrest) - biomarkers: he has been a promoter of a project on biomarkers (BNP) in acute coronary syndromes and heart failure. He is currently also the promoter of a project on the analysis of exhaled air as a rapid diagnostic test to distinguish between heart failure, infarction and lung disease. Within the field of valvular heart disease, he has mainly focused on mitral valve regurgitation and started following projects. - Treatment by percutaneous MitraClip placement: he is the founder and driving force behind the Mitrabel registration (Belgian registration of MitraClip interventions) with the aim to better evaluate the value of this new technique and to optimize the selection of the right patients. - Causes and treatment of atrial functional mitral regurgitation. He has set up studies to investigate which factors (AF, obesity, hypertension, diastolic heart failure) play a role in the development of mitral valve regurgitation due to atrial remodeling. He is also investigating whether MitraClip treatment can also be applied to severe atrial functional MR
AbstractThis project represents a formal research agreement between UA and on the other hand the Hercules Foundation. UA provides the Hercules Foundation research results mentioned in the title of the project under the conditions as stipulated in this contract.
- Promotor: De Meyer Guido
- Co-promotor: Claeys Marc
- Co-promotor: D'Haese Patrick
- Co-promotor: De Keulenaer Gilles
- Co-promotor: Loeys Bart
- Co-promotor: Vrints Christiaan
AbstractIn this study, we will investigate the role of autophagy (a cell survival and death pathway) and adiponectin (an endogenous hormone produced by fat cells) in a protective post-myocardial infarction reperfusion therapy called postconditioning. Adiponectin has protective myocardial effects that limit lethal reperfusion injury. However, patients with central obesity have low plasma levels of adiponectin, which may confound the cardioprotective properties of postconditioning.
- Promotor: Vrints Christiaan
- Co-promotor: Claeys Marc
- Co-promotor: De Meyer Guido
- Co-promotor: Martinet Wim
- Co-promotor: Timmermans Jean-Pierre